Episode summary
Indexes Edge Higher As Fed Stands Pat: Brinker, Medpace, Iovance In Focus | Stock Market Today
Summary
The major indexes finished modestly higher after the Fed left rates unchanged, but the market still looks uneven beneath the surface. The Nasdaq Composite tested its converged 21-day and 50-day moving averages, while the S&P 500 stayed above its reclaimed short-term support and small caps held above the 200-day line. The host and analyst framed the session as a late-day bounce rather than a decisive breakout, with inflation data due the next morning and Treasury yields edging higher.
Earnings drove the biggest stock moves. Oracle jumped after a bullish long-term revenue outlook, but the analyst said the move was more of a rebound in a beaten-down megacap than a broad-market catalyst. Brinker International stood out as a cleaner earnings winner, with strong same-store sales and traffic helping the Chili’s parent reclaim its 50-day line. Medpace also looked constructive as a contract research leader in a strong medical group, while Iovance Biotherapeutics was highlighted as a tightly acting biotech with innovative cancer therapy and heavy trading volume.
After the close, Microsoft traded higher on better-than-expected Azure growth and solid relative strength, while Alphabet dropped sharply as investors focused on cash flow and capex concerns. The analyst also flagged weakness in security software names like Fortinet and ServiceNow, alongside continued strength in select health care and biotech stocks.
Key takeaways
- The analyst said the Nasdaq is still fighting resistance at the converged 21-day and 50-day moving averages, making tomorrow’s inflation data and earnings reactions key.
- Brinker International’s 10.1% same-store sales growth and 6.4% customer traffic helped the stock regain its 50-day line on strong volume.
- Medpace remains in a buy zone, with the analyst pointing to a strong relative strength line and a healthy contract research organization group.
- Iovance Biotherapeutics was described as an institutional-quality biotech with a tightly held breakout pattern and innovative cancer immunotherapy.
- Microsoft’s positive after-hours reaction contrasted with Alphabet’s selloff, underscoring how AI spend, cash flow, and capex are driving tech-stock selection.
Notable quotes
“the major indexes at some key levels ahead of more big earnings reports. We do have the Fed now behind us perhaps at least the day one reaction”
“we managed to get uh a little bit of green in the in the market, so we'll we'll take it”
“I don't know that it had uh conquered it uh at at the close. I didn't uh check, but it uh still getting some resistance there as far as as far as I could tell”
“this is a stock I you know it it it is actionable for for some traders”
Topics
- fed policy
- market indexes
- stock picks
- brinker
- medpace iovance
Companies and tickers mentioned
- EAT
- MEDP
- IOVA
- Brinker
- Medpace
- Iovance
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Stock Market Today With Ibd
-
Defense Key As Stocks Lose Ground; Humana, Appian, Sezzle In Focus | Stock Market Today -
Indexes Vulnerable At Key Levels; Toast, Docusign, Crocs In Focus | Stock Market Today -
Stocks Weather Nvidia News; Arista Networks, Five Below, Cloudflare In Focus | Stock Market Today -
Nasdaq Surges As AI Stocks Lead Tech Rebound; CRWV, AMD, TXN In Focus | Stock Market Today -
Indexes Fall As Consumer Prices Turn Hot: SEI Investments, FAST, FIVE In Focus | Stock Market Today -
Rebound Gets Stronger; Is It Enough? BrightSpring, Block In Focus | Stock Market Today
Stock Market Today With Ibd, this episode and its artwork belong to their owners. Octagon is not affiliated with the show; this page is an independent summary.